ACC 2019 The randomized INFINITY trial showed a significant reduction in accrual of subcortical white matter disease in older people receiving more intensive antihypertensive therapy, but mobility and cognitive function were not improved.

ACC 2019 Post-approval analyses of the CardioMEMS PAS trial showed that adapting therapy based on pulmonary artery pressure is effective in reducing hospitalizations for HF and safe in patients with NYHA class III HF.

ACC 2019 The COACT trial did not show improved survival at 90 days with immediate vs. delayed coronary angiography in NSTEMI patients with return of spontaneous circulation after out-of-hospital cardiac arrest.

ACC 2019 Janet Wyman summarizes the results of the PARTNER 3 trial, comparing TAVR with surgery in patients with aortic stenosis. The results will cause a paradigm flip in treatment of these patients and in communicating the treatment plan with them.

ACC 2019 Icosapent ethyl reduces total ischemic events and first and recurrent events compared to placebo. Prof Bhatt explains the results of the REDUCE-IT trial and what this means for high risk patients.

ACC 2019 Dr. Adam DeVore discusses the results of an open-label extension study of PIONEER-HF. In this study, the effect of sacubitril/valsartan in acute HF was confirmed, showing greatest benefit when started early during hospitalisation.

ACC 2019 The results of the CLEAR WIsdom trial are summarized by prof Goldberg, with lowering of LDL-c in response to bempedoic acid vs placebo as most important finding.

ACC 2019 The STOPDAPT-2 and SMART-CHOICE trials both showed that shorter duration of DAPT was non-inferior to 12 months DAPT for ischemic outcomes with reduced bleeding after drug-eluting stent implantation.

ACC 2019 A total events analysis of REDUCE-IT showed that icosapent ethyl can not only reduce first events by 25%, but also second, third or further events by 32%, 31% and 48%, respectively.

ACC 2019 An analysis of DECLARE-TIMI 58 showed that dapagliflozin was associated with reduced hospitalization for HF and CV death across a range of EF. Benefit seems largest in HFrEF.

ACC 2019 Results of the CLEAR Wisdom trial showed that bempedoic acid lowered LDL-c in high CV risk patients with elevated LDL-c levels who are on maximally tolerated statin and/or other lipid-modifying therapies.

ACC 2019 Long-term data of the POET trial now show that switching to oral antibiotics is safe and effective for up to 3.5 years. Oral treatment may halve the length of the hospital stay.